Current druggable targets for therapeutic control of Alzheimer's disease

Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer’s disease

(2020) Kenta Yoshida et al.   Alzheimers Research & Therapy

Selected LDLR and APOE Polymorphisms Affect Cognitive and Functional Response to Lipophilic Statins in Alzheimer’s Disease

(2020) Fabricio Ferreira de Oliveira et al.   JOURNAL OF MOLECULAR NEUROSCIENCE

Discontinued disease-modifying therapies for Alzheimer’s disease: status and future perspectives

(2020) Bruno P. Imbimbo et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Innovative Therapy for Alzheimer’s Disease-With Focus on Biodelivery of NGF

(2019) Sumonto Mitra et al.   Frontiers in Neuroscience

The Role of NMDA Receptors in Alzheimer’s Disease

(2019) Jinping Liu et al.   Frontiers in Neuroscience

A clinical dose of angiotensin-converting enzyme (ACE) inhibitor and heterozygous ACE deletion exacerbate Alzheimer’s disease pathology in mice

(2019) Shuyu Liu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Randomized Trial of Verubecestat for Prodromal Alzheimer’s Disease

(2019) Michael F. Egan et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Evolution of Tau Phosphorylation and Interactions

(2019) Nataliya I. Trushina et al.   Frontiers in Aging Neuroscience

Cholinesterase Inhibitors for Alzheimer's Disease: Multitargeting Strategy Based on Anti-Alzheimer's Drugs Repositioning

(2019) Md. Tanvir Kabir et al.   CURRENT PHARMACEUTICAL DESIGN

Investigational BACE inhibitors for the treatment of Alzheimer’s disease

(2019) Bruno P. Imbimbo et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Pharmacogenetics of Angiotensin-Converting Enzyme Inhibitors in Patients with Alzheimer's Disease Dementia

(2018) Fabricio Ferreira de Oliveira et al.   Current Alzheimer Research

Microglia and Astrocytes in Alzheimer's Disease: Implications for Therapy

(2018) Marc Fakhoury   Current Neuropharmacology

Memantine for the Treatment of Dementia: A Review on its Current and Future Applications

(2018) Jaume Folch et al.   JOURNAL OF ALZHEIMERS DISEASE

Una revisión de los avances en la terapéutica de la enfermedad de Alzheimer: estrategia frente a la proteína β-amiloide

(2018) J. Folch et al.   NEUROLOGIA

Current Concepts of Neurodegenerative Mechanisms in Alzheimer’s Disease

(2018) Kasthuri Bai Magalingam et al.   Biomed Research International

A promising connection between BDNF and Alzheimer’s disease

(2018) Maria Laura Giuffrida et al.   Aging-US

Effect of Neocortical and Hippocampal Amyloid Deposition upon Galaninergic and Cholinergic Neurites in AβPPswe/PS1ΔE9 Mice

(2018) Christy M. Kelley et al.   JOURNAL OF ALZHEIMERS DISEASE

Angiotensin Converting Enzyme Inhibitors and the Reduced Risk of Alzheimer's Disease in the Absence of Apolipoprotein E4 Allele

(2018) Wei Qiao Qiu et al.   JOURNAL OF ALZHEIMERS DISEASE

TAK-071, a novel M1 positive allosteric modulator with low cooperativity, improves cognitive function in rodents with few cholinergic side effects

(2018) Yuu Sako et al.   NEUROPSYCHOPHARMACOLOGY

Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial

(2018) Brian Lawlor et al.   PLOS MEDICINE

Riluzole reduces amyloid beta pathology, improves memory, and restores gene expression changes in a transgenic mouse model of early-onset Alzheimer’s disease

(2018) Masahir Okamoto et al.   Translational Psychiatry

NGF-Dependent Changes in Ubiquitin Homeostasis Trigger Early Cholinergic Degeneration in Cellular and Animal AD-Model

(2018) Valentina Latina et al.   Frontiers in Cellular Neuroscience

Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer’s Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial

(2017) Gordon K. Wilcock et al.   JOURNAL OF ALZHEIMERS DISEASE

Therapeutics of Neurotransmitters in Alzheimer’s Disease

(2017) Ramesh Kandimalla et al.   JOURNAL OF ALZHEIMERS DISEASE

Bryostatin Effects on Cognitive Function and PKCɛ in Alzheimer’s Disease Phase IIa and Expanded Access Trials

(2017) Thomas J. Nelson et al.   JOURNAL OF ALZHEIMERS DISEASE

Oxidative Stress, Synaptic Dysfunction, and Alzheimer’s Disease

(2017) Eric Tönnies et al.   JOURNAL OF ALZHEIMERS DISEASE

Amyloid-Beta and Phosphorylated Tau Accumulations Cause Abnormalities at Synapses of Alzheimer’s disease Neurons

(2017) Ravi Rajmohan et al.   JOURNAL OF ALZHEIMERS DISEASE

Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial

(2017) Petr Novak et al.   LANCET NEUROLOGY

Hippocampal neurophysiology is modified by a disease-associated C-terminal fragment of tau protein

(2017) Francesco Tamagnini et al.   NEUROBIOLOGY OF AGING

A phase 3 trial of IV immunoglobulin for Alzheimer disease

(2017) Norman R. Relkin et al.   NEUROLOGY

Semagacestat Is a Pseudo-Inhibitor of γ-Secretase

(2017) Shinji Tagami et al.   Cell Reports

Role of BACE1 in Alzheimer’s synaptic function

(2017) Brati Das et al.   Translational Neurodegeneration

2016 Alzheimer's disease facts and figures

(2016)   Alzheimers & Dementia

Vitamin B1 (thiamine) and dementia

(2016) Gary E. Gibson et al.   Annals of the New York Academy of Sciences

Neuroprotective Mechanisms Mediated by CDK5 Inhibition

(2016) Gohar Mushtaq et al.   CURRENT PHARMACEUTICAL DESIGN

Oxidative stress: A major pathogenesis and potential therapeutic target of antioxidative agents in Parkinson’s disease and Alzheimer’s disease

(2016) Tianfang Jiang et al.   PROGRESS IN NEUROBIOLOGY

Alzheimer’s disease-associated mutations increase amyloid precursor protein resistance to γ-secretase cleavage and the Aβ42/Aβ40 ratio

(2016) Ting-Hai Xu et al.   Cell Discovery

Analyzing dendritic spine pathology in Alzheimer’s disease: problems and opportunities

(2015) Mario M. Dorostkar et al.   ACTA NEUROPATHOLOGICA

Neurotrophic Factors and Their Potential Applications in Tissue Regeneration

(2015) Nan Xiao et al.   ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS

The Role of Cdk5 in Alzheimer’s Disease

(2015) Shu-Lei Liu et al.   MOLECULAR NEUROBIOLOGY

CHF5074 (CSP-1103) induces microglia alternative activation in plaque-free Tg2576 mice and primary glial cultures exposed to beta-amyloid

(2015) V. Porrini et al.   NEUROSCIENCE

Tau immunotherapy for Alzheimer's disease

(2015) Jan Torleif Pedersen et al.   TRENDS IN MOLECULAR MEDICINE

Alzheimer disease: Epidemiology, diagnostic criteria, risk factors and biomarkers

(2014) Christiane Reitz et al.   BIOCHEMICAL PHARMACOLOGY

Strategy to reduce free radical species in Alzheimer’s disease: an update of selected antioxidants

(2014) Fabio Di Domenico et al.   Expert Review of Neurotherapeutics

Neuroinflammation in the pathogenesis of Alzheimer’s disease. A rational framework for the search of novel therapeutic approaches

(2014) Inelia Morales et al.   Frontiers in Cellular Neuroscience

Frontiers in therapeutic development of allopregnanolone for Alzheimer’s disease and other neurological disorders

(2014) Ronald W. Irwin et al.   Frontiers in Cellular Neuroscience

γ-Secretase inhibitors and modulators

(2013) Todd E. Golde et al.   BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES

Potential novel targets for Alzheimer pharmacotherapy: II. Update on secretase inhibitors and related approaches

(2013) J. A. Mikulca et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Progress and Developments in Tau Aggregation Inhibitors for Alzheimer Disease

(2013) Bruno Bulic et al.   JOURNAL OF MEDICINAL CHEMISTRY

Alzheimer's Aβ42 and Aβ40 peptides form interlaced amyloid fibrils

(2013) Lei Gu et al.   JOURNAL OF NEUROCHEMISTRY

A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease

(2013) Rachelle S. Doody et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Clinical Problem of Symptomatic Alzheimer Disease and Mild Cognitive Impairment

(2013) R. Tarawneh et al.   Cold Spring Harbor Perspectives in Medicine

Alzheimer Mechanisms and Therapeutic Strategies

(2012) Yadong Huang et al.   CELL

Acitretin, an Enhancer of Alpha-Secretase Expression, Crosses the Blood-Brain Barrier and Is Not Eliminated by P-Glycoprotein

(2012) David Holthoewer et al.   Neurodegenerative Diseases

Age-dependent neuroinflammatory responses and deficits in long-term potentiation in the hippocampus during systemic inflammation

(2012) X. Liu et al.   NEUROSCIENCE

Tau-targeted treatment strategies in Alzheimer's disease

(2011) Jürgen Götz et al.   BRITISH JOURNAL OF PHARMACOLOGY

γ-Secretase Inhibitors and Modulators for the Treatment of Alzheimer's Disease: Disappointments and Hopes

(2011) Bruno P. Imbimbo et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Unknown

(2011) Daniel Paris et al.   MOLECULAR MEDICINE

Potential therapeutic uses of BDNF in neurological and psychiatric disorders

(2011) Alan H. Nagahara et al.   NATURE REVIEWS DRUG DISCOVERY

Alzheimer's Disease: The Challenge of the Second Century

(2011) D. M. Holtzman et al.   Science Translational Medicine

The roles of amyloid precursor protein (APP) in neurogenesis

(2011) Zhi-dong Zhou et al.   Cell Adhesion & Migration

Dietary Antioxidants and Long-term Risk of Dementia

(2010) Elizabeth E. Devore et al.   ARCHIVES OF NEUROLOGY

Epothilone D Improves Microtubule Density, Axonal Integrity, and Cognition in a Transgenic Mouse Model of Tauopathy

(2010) K. R. Brunden et al.   JOURNAL OF NEUROSCIENCE

A  Oligomers Cause Localized Ca2+ Elevation, Missorting of Endogenous Tau into Dendrites, Tau Phosphorylation, and Destruction of Microtubules and Spines

(2010) H. Zempel et al.   JOURNAL OF NEUROSCIENCE

Amyloid-β–induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks

(2010) Jorge J Palop et al.   NATURE NEUROSCIENCE

The secretases: enzymes with therapeutic potential in Alzheimer disease

(2010) Bart De Strooper et al.   Nature Reviews Neurology

Neurochemical basis for symptomatic treatment of Alzheimer's disease

(2010) Paul T. Francis et al.   NEUROPHARMACOLOGY

The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer's disease and related tauopathies

(2010) Kurt R. Brunden et al.   PHARMACOLOGICAL RESEARCH

Cholinergic Involvement in Alzheimer’s Disease. A Link with NGF Maturation and Degradation

(2009) A. Claudio Cuello et al.   JOURNAL OF MOLECULAR NEUROSCIENCE

Amyloid β-Induced Nerve Growth Factor Dysmetabolism in Alzheimer Disease

(2009) Martin A. Bruno et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

New insights into clinical trial for colostrinin™ in Alzheimer’s disease

(2009) P. Szaniszlo et al.   Journal of Nutrition Health & Aging

A novel GSK-3β inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo

(2009) L. Serenó et al.   NEUROBIOLOGY OF DISEASE

An Overview of APP Processing Enzymes and Products

(2009) Vivian W. Chow et al.   NEUROMOLECULAR MEDICINE

Cholinergic treatments with emphasis on M1 muscarinic agonists as potential disease-modifying agents for Alzheimer’s disease

(2008) Abraham Fisher   Neurotherapeutics